Fig. 9From: Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancersImmunofluorescent staining assays to measure the status of STING pathway, TGF-β signal, and epithelial-mesenchymal transition in the B16 model. The representative images of a α-p-TBK1 staining, b α-TGF-β1 staining, (c) α-SMA and α-Vimentin staining (n = 5 biological replicates). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 denote the significant difference relative to combination treatmentBack to article page